"A Study to Assess Efficacy and Safety of Oral Tazemetostat in Adult Participants With Relapsed/Refractory Follicular Lymphoma That Does Not Have an EZH2 Gain-of-function Genetic Mutation"

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 2, 2025

Primary Completion Date

April 6, 2029

Study Completion Date

April 6, 2029

Conditions

Follicular LymphomaRefractory Follicular Lymphoma

Interventions

DRUG

Tazverik (Tazemetostat)

Oral Tablet